Pacific Biosciences of California, Inc. Amortization of Debt Issuance Costs
Pacific Biosciences of California, Inc. (PACB) reported Amortization of Debt Issuance Costs of $156.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2023-05-04
- Pacific Biosciences of California, Inc. amortization of debt issuance costs for the quarter ending 2023-03-31 was $156.00K, a 1.96% increase year-over-year.
- Pacific Biosciences of California, Inc. amortization of debt issuance costs for the quarter ending 2022-12-31 was $155.00K, a 1.31% increase year-over-year.
- Pacific Biosciences of California, Inc. amortization of debt issuance costs for the quarter ending 2022-09-30 was $154.00K, a 1.32% increase year-over-year.
- Pacific Biosciences of California, Inc. amortization of debt issuance costs for the quarter ending 2022-06-30 was $154.00K, a 1.99% increase year-over-year.
- Pacific Biosciences of California, Inc. amortization of debt issuance costs for fiscal 2022 was $617.00K, a 15.98% increase from fiscal 2021.
- Pacific Biosciences of California, Inc. amortization of debt issuance costs for fiscal 2021 was $532.00K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2023-03-31 | $156.00K 10-Q · filed 2023-05-04 | $311.00K derived: sum of 2 quarters · filed 2023-05-04 | $465.00K derived: sum of 3 quarters · filed 2023-05-04 | $619.00K derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-12-31 | $155.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $309.00K derived: sum of 2 quarters · filed 2023-02-28 | $463.00K derived: sum of 3 quarters · filed 2023-02-28 | $617.00K 10-K · filed 2023-02-28 |
| 2022-09-30 | $154.00K 10-Q · filed 2022-11-08 | $308.00K derived: sum of 2 quarters · filed 2022-11-08 | $462.00K 10-Q · filed 2022-11-08 | $614.00K derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-06-30 | $154.00K 10-Q · filed 2022-08-08 | $307.00K 10-Q · filed 2022-08-08 | $460.00K derived: sum of 3 quarters · filed 2023-05-04 | $612.00K derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-03-31 | $153.00K 10-Q · filed 2023-05-04 | $306.00K derived: sum of 2 quarters · filed 2023-05-04 | $458.00K derived: sum of 3 quarters · filed 2023-05-04 | $609.00K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $153.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $305.00K derived: sum of 2 quarters · filed 2023-02-28 | $456.00K derived: sum of 3 quarters · filed 2023-02-28 | $532.00K 10-K · filed 2023-02-28 |
| 2021-09-30 | $152.00K 10-Q · filed 2022-11-08 | $303.00K derived: sum of 2 quarters · filed 2022-11-08 | $379.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $151.00K 10-Q · filed 2022-08-08 | $227.00K 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $74.00K 10-Q · filed 2021-05-06 | |||
| 2013-03-31 | -$2.00K 10-Q · filed 2013-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |